Entering text into the input field will update the search result below

Abeona's ABO-202 an Orphan Drug in Europe for Batten disease; shares up 4% premarket

Apr. 20, 2018 8:42 AM ETAbeona Therapeutics Inc. (ABEO) StockBy: Douglas W. House, SA News Editor1 Comment
  • Abeona Therapeutics (NASDAQ:ABEO) is up 4% premarket on light volume on the heels of its announcement that the European Medicines Agency has designated gene therapy ABO-202 an Orphan Drug for the treatment of neuronal ceroid lipofuscinosis, known as Batten disease, a fatal inherited lysosomal storage disorder that primarily affects the nervous system in children.
  • Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.

Recommended For You

About ABEO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABEO--
Abeona Therapeutics Inc.